• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

ACS Infect Dis . Chemoenzymatic Synthesis of SARS-CoV-2 Homogeneous O-Linked Glycopeptides for Exploring Their Inhibition Functions

tetano

Editor, Senior Moderator
ACS Infect Dis


. 2022 Sep 12.
doi: 10.1021/acsinfecdis.2c00383. Online ahead of print.
Chemoenzymatic Synthesis of SARS-CoV-2 Homogeneous O-Linked Glycopeptides for Exploring Their Inhibition Functions


Yongheng Rong[SUP] 1 [/SUP], Xingyun Wang[SUP] 2 [/SUP], Weian Mao[SUP] 1 [/SUP], Fang Yuan[SUP] 1 [/SUP], Min Chen[SUP] 1 [/SUP], Shengjun Wang[SUP] 3 [/SUP], Peng George Wang[SUP] 2 [/SUP], Zhigang Wu[SUP] 4 [/SUP], Yunjiao He[SUP] 2 [/SUP], Yun Kong[SUP] 1 [/SUP]



Affiliations

Abstract

Harnessing highly conserved peptides derived from the receptor binding domain (RBD) of spike (S) protein to construct peptide-based inhibitors is one of the most effective strategies to fight against the ever-mutating coronavirus SARS-CoV-2. But how the O-glycosylation affects their inhibition abilities has not been intensively explored. Herein, an intrinsic O-glycosylated peptide P[SUB]320-334[/SUB] derived from RBD was screened and homogeneous O-linked glycopeptides containing Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures were first synthesized via chemoenzymatic strategies. Compared with the unglycosylated peptide, the binding of sT-P[SUB]320-334[/SUB] to hACE2 was enhanced to 133% and the inhibition capacity against RBD-hACE2 binding of sTn- and sT-P[SUB]320-334[/SUB] was significantly increased up to 150-410%. Thus, our results suggest the sialic acid residue on the terminal of short O-glycan structures might strengthen the inhibition capacities of these peptide-based inhibitors, which might provide novel optimization directions for the inhibitor design.

Keywords: O-glycosylation modification; SARS-CoV-2; chemoenzymatic synthesis; peptide-based inhibitor; spike protein.
 
Back
Top Bottom